^
    Back
    Association details:
    Biomarker:Chr del(5)(q31)
    Cancer:Myelodysplastic Syndrome
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Blood
    Title:

    A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    Excerpt:
    In conclusion, in this phase 3, randomized, placebo-controlled study in patients with IPSS Low- or Intermediate-1-risk MDS with del5q31, both lenalidomide doses (5 mg and 10 mg) resulted in significant RBC-TI and cytogenetic responses and were generally well tolerated with a manageable safety profile.
    DOI:
    10.1182/blood-2011-01-330126
    Trial ID:
    NCT00179621
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

    Excerpt:
    ...Diagnosis of low or intermediate-1-risk International Prognostic Scoring System (IPSS) Myelodysplastic Syndromes (MDS) without an abnormality of chromosome 5 involving a deletion between bands q31 and q33...
    Trial ID:
    NCT00065156
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    N Engl J Med
    Title:

    Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

    Excerpt:
    Of the 148 patients who received lenalidomide, 112 (76%) had a response to the treatment...Lenalidomide can reduce transfusion requirements and reverse cytologic and cytogenetic abnormalities in patients who have the myelodysplastic syndrome with the 5q31 deletion.
    DOI:
    10.1056/NEJMoa061292
    Trial ID:
    NCT00065156